Replimune Group (NASDAQ:REPL) Given New $9.00 Price Target at Wedbush

Replimune Group (NASDAQ:REPL) had its target price lifted by analysts at Wedbush from $6.00 to $9.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Wedbush’s target price would indicate a potential downside of 19.64% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Piper Sandler lowered shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a research note on Friday, April 10th. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. BMO Capital Markets downgraded shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research note on Monday, April 13th. Jefferies Financial Group restated a “hold” rating and issued a $2.00 price objective (down from $13.00) on shares of Replimune Group in a report on Monday, April 13th. Finally, JPMorgan Chase & Co. raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 price objective on the stock in a research report on Friday. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Replimune Group has an average rating of “Reduce” and a consensus price target of $6.38.

Replimune Group Stock Performance

Shares of REPL stock opened at $11.20 on Tuesday. The stock has a fifty day moving average of $6.41 and a 200 day moving average of $7.29. Replimune Group has a 52 week low of $1.50 and a 52 week high of $13.24. The firm has a market capitalization of $924.78 million, a price-to-earnings ratio of -3.26 and a beta of 0.88. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, research analysts expect that Replimune Group will post -3.39 earnings per share for the current year.

Insider Activity at Replimune Group

In other news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Hedge funds have recently bought and sold shares of the business. International Assets Investment Management LLC purchased a new stake in Replimune Group in the fourth quarter worth about $29,000. CWM LLC lifted its holdings in shares of Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after purchasing an additional 2,886 shares during the last quarter. Essential Partners LLC lifted its holdings in shares of Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after purchasing an additional 5,624 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after purchasing an additional 1,879 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Replimune Group in the 2nd quarter worth approximately $69,000. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.